Focus Partners Wealth
AZN icon

Focus Partners Wealth’s AstraZeneca AZN Stock Holding History

Focus Partners Wealth’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
81,265
+12,315
+18% +$2.32M 0.02% 580
2026
Q1 		$13.6M Buy
68,950
+4,999
+8% +$964K 0.02% 619
2025
Q4 		$11.6M Buy
63,951
+12,853
+25% +$2.25M 0.01% 655
2025
Q3 		$7.89M Buy
51,098
+9,576
+23% +$1.45M 0.01% 626
2025
Q2 		$5.8M Buy
41,522
+1,702
+4% +$239K 0.01% 635
2025
Q1 		$5.85M Buy
39,820
+4,799
+14% +$694K 0.01% 587
2024
Q4 		$4.59M Buy
35,021
+3,367
+11% +$471K 0.01% 634
2024
Q3 		$4.92M Buy
31,654
+9,383
+42% +$1.51M 0.02% 565
2024
Q2 		$3.47M Buy
22,271
+2,549
+13% +$384K 0.01% 560
2024
Q1 		$2.67M Buy
19,722
+5,037
+34% +$667K 0.02% 435
2023
Q4 		$1.98M Buy
+14,685
New +$1.91M 0.03% 356

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Focus Partners Wealth's AZN Position: Q2 2026 in Review

Focus Partners Wealth increased its AstraZeneca (AZN) stake by 18% in Q2 2026, buying an estimated $2.32M and bringing the position to 81,265 shares worth $15.4M. The position accounts for 0.02% of the portfolio, ranked #580.

Focus Partners Wealth first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Focus Partners Wealth held 81,265 shares of AstraZeneca worth $15.4M as of Q2 2026.
  • Focus Partners Wealth bought 12,315 AstraZeneca shares in Q2 2026, an estimated $2.32M.
  • AstraZeneca made up 0.02% of Focus Partners Wealth's portfolio in Q2 2026, its #580 holding.
  • Focus Partners Wealth first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.